Clinical Trial Update: A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial of sotatercept for Eisenmenger syndrome or unrepaired shunt-associated pulmonary arterial hypertension resistant to vasodilator therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eisenmenger Syndrome
• Pulmonary Arterial Hypertension Due to Congenital Heart Disease

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Kazuya Hosokawa | Conditions: Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease | Phase 4 | Status: RECRUITING